Khatri, M., Naughton, R
The Society welcomes NICEs endorsement of lebrikizumab as an additional treatment option for eligible individuals with moderate to severe atopic eczema, emphasizing the importance of providing diverse treatment choices to match patients needs. Jorgen Damsbo, General Manager at Almirall, UK, remarked, The NICE recommendation for lebrikizumab reflects its proven effectiveness with 4-weekly maintenance dosing and a favorable safety profile, aligning with our commitment to improving patients lives by helping them achieve better health. Professor Tony Bewley, Consultant Dermatologist at Barts Health NHS Trust and Honorary Professor of Dermatology at QMUL, emphasized the significant psychosocial burden of atopic dermatitis, noting that lebrikizumabs approval marks a crucial advancement that is welcomed by both patients and clinicians
Approximately 4 in 10 U.S
The full 2025 list is available at dallasnews.com/top-workplaces-dfw
Sergey Terushkin, MD, FACS , who has extensive experience helping patients achieve their wellness and weight management goals through evidence-based treatment plans
The development and testing of nanocages is ongoing to ensure readiness for clinical trials